Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 120 matching drugs for HDAC4 — including drugs targeting any of its 47 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
pharmacological study, romidepsin HDAC4 Direct 2
romidepsin HDAC4 Direct 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule HDAC4 Direct 1
romidepsin, laboratory biomarker analysis HDAC4 Direct 1
belinostat HDAC4 Direct yes 0
panobinostat HDAC4 Direct yes 0
panobinostat lactate HDAC4 Direct yes 0
romideps HDAC4 Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC3 SSL via HDAC3 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab SRC SSL via SRC 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab, guadecitabine, mocetinostat HDAC3 SSL via HDAC3 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC3 SSL via HDAC3 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC2 SSL via HDAC2 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy PPARG SSL via PPARG 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC2 SSL via HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid PPARG SSL via PPARG 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
atorvastatin, temozolomide, radiotherapy HDAC2 SSL via HDAC2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC2 SSL via HDAC2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC3 SSL via HDAC3 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
bevacizumab, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
bevacizumab, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor HDAC2 SSL via HDAC2 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor HDAC3 SSL via HDAC3 1
curcumin PPARG SSL via PPARG 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
dimethyl fumarate, temozolomide, radiation therapy RELA SSL via RELA 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 SSL via PIK3R1 1
enzastaurin, lomustine PIK3R1 SSL via PIK3R1 1
enzastaurin, temozolomide, radiation therapy PIK3R1 SSL via PIK3R1 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy PPARG SSL via PPARG 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff HDAC2 SSL via HDAC2 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff HDAC3 SSL via HDAC3 1
glipizide PPARG SSL via PPARG 1
irinotecan, cisplatin, simvastatin HDAC2 SSL via HDAC2 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
medical cannabis PPARG SSL via PPARG 1
nabiximols, temozolomide, nabiximols-matched placebo PPARG SSL via PPARG 1
pembrolizumab, vorinostat, temozolomide, radiotherapy HDAC2 SSL via HDAC2 1
pembrolizumab, vorinostat, temozolomide, radiotherapy HDAC3 SSL via HDAC3 1
pioglitazone, pioglitazone PPARG SSL via PPARG 1
ponatinib SRC SSL via SRC 1
romidepsin HDAC2 SSL via HDAC2 yes 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule HDAC2 SSL via HDAC2 1
romidepsin, laboratory biomarker analysis HDAC2 SSL via HDAC2 1
sorafenib tosylate, valproic acid, sildenafil citrate HDAC2 SSL via HDAC2 1
sorafenib tosylate, valproic acid, sildenafil citrate PPARG SSL via PPARG 1
sulfasalazine PPARG SSL via PPARG 1
valproic acid HDAC2 SSL via HDAC2 1
valproic acid PPARG SSL via PPARG 1
valproic acid, bevacizumab, radiation therapy HDAC2 SSL via HDAC2 1
valproic acid, bevacizumab, radiation therapy PPARG SSL via PPARG 1
valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine HDAC2 SSL via HDAC2 1
valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine PPARG SSL via PPARG 1
vorinostat, bevacizumab HDAC2 SSL via HDAC2 1
vorinostat, bevacizumab HDAC3 SSL via HDAC3 1
vorinostat, bevacizumab, irinotecan HDAC2 SSL via HDAC2 1
vorinostat, bevacizumab, irinotecan HDAC3 SSL via HDAC3 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis HDAC2 SSL via HDAC2 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis HDAC3 SSL via HDAC3 1
vorinostat, conventional surgery HDAC2 SSL via HDAC2 1
vorinostat, conventional surgery HDAC3 SSL via HDAC3 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study HDAC2 SSL via HDAC2 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study HDAC3 SSL via HDAC3 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration HDAC2 SSL via HDAC2 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration HDAC3 SSL via HDAC3 1
vorinostat, therapeutic conventional surgery, bortezomib HDAC2 SSL via HDAC2 1
vorinostat, therapeutic conventional surgery, bortezomib HDAC3 SSL via HDAC3 1
balsalazide PPARG SSL via PPARG yes 0
balsalazide disodium PPARG SSL via PPARG yes 0
belinostat HDAC2 SSL via HDAC2 yes 0
belinostat HDAC3 SSL via HDAC3 yes 0
belinostat HDAC5 SSL via HDAC5 yes 0
bezafibrate PPARG SSL via PPARG yes 0
dasatinib SRC SSL via SRC yes 0
dextrothyroxine THRB SSL via THRB yes 0
dextrothyroxine sodium THRB SSL via THRB yes 0
levothyroxine THRB SSL via THRB yes 0
levothyroxine sodium THRB SSL via THRB yes 0
liothyronine THRB SSL via THRB yes 0
liothyronine sodium THRB SSL via THRB yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.